Sarepta Therapeutics (SRPT) PT Raised to $176 at BofA Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Sarepta Therapeutics (SRPT) to resume trading at 7:10AM ET following a positive FDA AdCom vote
May 15, 2023 6:51 AM EDTSarepta Therapeutics (NASDAQ: SRPT) is set to resume trading at 7:10AM ET following a positive FDA AdCom vote on DMD treatment SRP-9001.
... MoreSarepta (SRPT) could jump 30%+ following positive AdCom on DMD treatment SRP-9001
May 15, 2023 6:39 AM EDT(Updated - May 15, 2023 6:40 AM EDT)
Shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT), which are currently halted, are set to open higher Monday following a positive FDA Advisory Committee vote for Duchenne muscular dystrophy gene therapy treatment SRP-9001. One analyst thinks the stock can jump 33% today amid the news.
In a close vote 8 to 6 vote, the FDA U.S. Food and Drug Administration (FDA) Cellular, Tissue and Gene... More
